| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4dac022280ec96f54c694eb427655932 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-351
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-346
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-321
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-3181
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-317
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-318
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-315
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-33
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-345 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-113 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P17-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-113
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-711 |
| filingDate |
1998-10-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d1a0302739568216fff9e722927caa33
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e94a54ab88313bdf2a137306156b207b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_805d4f7a285b53e12e5c97d079bf2b7d |
| publicationDate |
2000-08-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-1030914-A2 |
| titleOfInvention |
Antisense oligonucleotides against tenascin for treating vitiligo |
| abstract |
The invention relates to specific, optionally modified oligonucleotides with a length of up to 18 nucleotides. Said oligonucleotides correspond to segments of tenascin-coding sequences or can bind to these sequences. The invention also relates to the production and use of the oligonucleotides, for example for the specific inhibition of the expression of tenascin and for producing medicaments used to treat vitiligo. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023131829-A1 |
| priorityDate |
1997-11-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |